Nordihydroguaiaretic acid improves metabolic dysregulation and aberrant hepatic lipid metabolism in mice by both PPARα-dependent and -independent pathways

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 304, Issue 1, 2013, Pages

  Zhang, Haiyan ^a   Shen, Wen Jun ^a   Cortez, Yuan ^b   Kraemer, Fredric B ^a   Azhar, Salman ^b  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

Dyslipidemia; Fatty liver; Gene array; Hepatic steatosis; Insulin resistance; Lipid oxidation; Ob ob mice

Indexed keywords

ANTILIPEMIC AGENT; CHEMOKINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; NORDIHYDROGUAIARETIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG MEGADOSE; DYSLIPIDEMIA; ENDOPLASMIC RETICULUM STRESS; FATTY ACID OXIDATION; FATTY LIVER; GENE EXPRESSION; GLUCOSE TOLERANCE; HYPERINSULINEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; LIVER CELL; LIVER WEIGHT; LOW DRUG DOSE; MALE; METABOLIC SYNDROME X; MICROARRAY ANALYSIS; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION;

ADIPOKINES; ANIMALS; DIET; ENDOPLASMIC RETICULUM STRESS; ENDORIBONUCLEASES; FATTY ACIDS; FATTY LIVER; GLUCOSE TOLERANCE TEST; HYPOLIPIDEMIC AGENTS; LEPTIN; LIPID METABOLISM; LIPID METABOLISM DISORDERS; LIPOPROTEINS, VLDL; LIPOXYGENASE INHIBITORS; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROARRAY ANALYSIS; MULTIGENE FAMILY; NORDIHYDROGUAIARETIC ACID; PPAR ALPHA; PROTEIN-SERINE-THREONINE KINASES; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRIGLYCERIDES;

EID: 84871897789     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00328.2012     Document Type: Article

References (80)

1. Akiyama TE, Nicol CJ, Fievet C, Staels B, Ward JM, Auwerx J, Lee SST, Gonzales FJ, Peters JM. Peroxisome proliferator-activated receptor-regulates lipid homeostasis, but is not associated with obesity: studies with congenic mouse lines. J Biol Chem 276: 39088-39093, 2001.
2. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 346: 1221-1229, 2002.
3. Boergesen M, Pedersen TÅ, Gross B, van Heeringen J, Hagenbeek D, Bindesbøll C, Caron S, Lalloyer F, Steffensen KR, Neb HI, Gustafsson JA, Stunnenberg HG, Stales B, Mandrup S. Genome-wide profiling of liver X receptor, retinoid X receptor and peroxisome proliferator-activated receptor-in mouse liver reveals extensive sharing of binding sites. Mol Cell Biol 32: 852-867, 2012.
4. Burgess SC, Iizuka K, Jeong NH, Harris RA, Kashiwaya Y, Veech RL, Kitazume T. Carbohydrate-response element-binding protein deletion alters substrate utilization producing an energy-deficient liver. J Biol Chem 283: 1670-1678, 2008.
5. Cha JY, Repa JJ. The liver receptor (LXR) and hepatic lipogenesis. The carbohydrate-response element-binding protein is a target gene of LXR. J Biol Chem 282: 743-751, 2007.
6. Chakravarty MV, Pan Z, Zhu Y, Tordjman K, Schneider JG, Coleman T, Turk J, Semenkovich CF. "New" hepatic fat activates PPAR to maintain glucose, lipid and cholesterol homeostasis. Cell Metab 1: 309-322, 2005.
7. Dowman JK, Armstrong MJ, Tomlinson JW, Newsome PN. Current therapeutic strategies in non-alcoholic fatty liver disease. Diabetes Obes Metab 13: 692-702, 2011.
8. Engelking LJ, Kuriyama H, Hammer RE, Horton JD, Brown MS, Goldstein JL, Liang G. Overexpression of Insig-1 in the livers of transgenic mice inhibits SREBP processing and reduces insulin-stimulated lipogenesis. J Clin Invest 113: 1168-1175, 2004.
9. Farnández-Alvarez A, Alvarez MS, Gonzalez R, Cucarella C, Muntané J, Casado M. Human SREBP1c expression in liver is directly regulated by peroxisome proliferator-activated receptor (PPAR). J Biol Chem 286: 21477-21477, 2011.
10. Finck BN, Kelly DP. PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. J Clin Invest 116: 615-622, 2006.
11. Folch J, Lees M, Sloane-Stanley GH. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 226: 497-509, 1957.
12. Gowri MS, Azhar RK, Kraemer FB, Reaven GM, Azhar S. Masoprocol decreases rat lipolytic activity by decreasing the phosphorylation of HSL. Am J Physiol Endocrinol Metab 279: E593-E600, 2000.
13. Greenfield V, Cheung O, Sanyal AJ. Recent advances in nonalcoholic fatty liver disease. Curr Opin Gastroenterol 24: 320-327, 2008.
14. Harano Y, Yasui K, Toyama T, Nakajima T, Mitsuyoshi H, Mimani M, Hirasawa T, Itoh Y, Okanoue T. Fentofibrate, a peroxisome proliferator-activated receptor alpha agonists, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver. Liver Int 26: 613-620, 2006.
15. Hashimoto T, Cook WS, Qi C, Yeldandi AV, Reddy JK, Rao MS. Defect in peroxisome proliferator activated receptor-inducible fatty acid oxidation determines the severity of hepatic steatosis in response to fasting. J Biol Chem 275: 28918-28928, 2000.
16. Hebbachi AM, Knight BL, Wiggins D, Patel DD, Gibbons GF. Peroxisome proliferator-activated receptor deficiency abolishes the response of lipogenic gene expression to re-feeding: Restoration of the normal response by activation of liver X receptor. J Biol Chem 283: 4866-4876, 2008.
17. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 109: 1125-1131, 2002.
18. Huang J, Jia Y, Fu T, Viswakarma N, Bai L, Rao S, Zhu Y, Borensztajn J, Reddy JK. Sustained activation of PPAR by endogenous ligands increases hepatic fatty acid oxidation and prevents obesity in ob/ob mice. FASEB J 26: 628-638, 2012.
19. Hwahng SH, Ki SH, Bae EJ, Kim HE, Kim SG. Role of adenosine monophosphate-activated protein kinase-p70 ribosomal S6 kinase-1 pathway in repression of liver X receptor-alpha-dependent lipogenic gene induction and hepatic steatosis by a novel class of dithiolethiones. Hepatology 49: 1913-1925, 2009.
20. Iizuka K, Miller B, Uyeda K. Deficiency of carbohydrate-activated transcription factor ChREBP prevents obesity and improves plasma glucose control in leptin-deficient (ob/ob) mice. Am J Physiol Endocrinol Metab 291: E358-E364, 2006.
21. Jeong YS, Kim D, Lee YS, Kim HJ, Han JY, Im SS, Chong HK, Kwon JK, Cho YH, Kim WK, Osborne TF, Horton JD. Integrated expression profiling and genome-wide analysis of ChREBP targets reveals the dual role for ChREBP in glucose-regulated gene expression. PLoS ONE 6: e22544, 2011.
22. Juaczak MJ, Lee AH, Journayvaz FR, Lee HY, Birkenfeld AL, Guigni BA, Kahn M, Samuel VT, Glimcher LH, Shulman GI. Dissociation of inositol-requiring enzyme (IRE1)-mediated c-Jun N-terminal kinase activation from hepatic insulin resistance in conditional X-box-binding protein-1 (XBP1) knock-out mice. J Biol Chem 287: 2558-2567, 2012.
23. Jump DB. Fatty acid regulation of hepatic lipid metabolism. Curr Opin Clin Nutr Metab Care 14: 115-120, 2011.
24. Kammoun HL, Chabanon H, Hainault I, Luquest S, Magnan C, Koike T, Ferré P, Foufelle F. GRP78 expression inhibits insulin and ER stress-induced SREBP-1c activation and reduces hepatic steatosis in mice. J Clin Invest 119: 1201-1215, 2009.
25. Kashi MR, Torres DM, Harrison SA. Current and emerging therapies in nonalcoholic fatty liver disease. Semin Liver Dis 28: 396-406, 2008.
26. Kawaguchi T, Osatomi K, Yamashita H, Kabashima T, Uyeda K. Mechanism for fatty acid "sparing" effect on glucose-induced transcription: regulation of carbohydrate responsive element-binding protein by AMP-activated protein kinase. J Biol Chem 277: 3829-3835, 2002.
27. Kelley GL, Allan G, Azhar S. High dietary fructose induces a hepatic response resulting in cholesterol and lipid dysregulation. Endocrinology 145: 548-555, 2004.
28. Kersten S, Seydoux J, Peters JM, Gonzalez FJ, Desvergne B, Wahli W. Peroxisome proliferator-activated receptor mediates the adoptive response to fasting. J Clin Invest 103: 1489-1498, 1999.
29. Khashab MA, Liangunsakul S, Chalasani N. Nonalcoholic fatty liver disease as a component of the metabolic syndrome. Curr Gastroenterol Rep 10: 73-80, 2008.
30. Kim CH, Younossi ZM. Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. Cleve Clin J Med 75: 721-728, 2008.
31. Knebel B, Haas J, Hartwig S, Jacob S, Köllmer C, Nitzgen U, Muller-Wieland D, Kotzka J. Liver-specific expression of transcriptionally active SREBP-1c is associated with fatty liver and increased visceral fat mass. PLoS ONE 7: e31812, 2012.
32. Knight BL, Hebbachi A, Hauton D, Brown AM, Wiggins D, Patel DD, Gibbons GF. A role for the PPAR in the control of SREBP activity and lipid synthesis in the liver. Biochem J 389: 413-421, 2005.
33. Kopec KL, Burns D. Nonalcoholic fatty liver disease: a review of the spectrum of disease, diagnosis, and therapy. Nutr Clin Pract 26: 565-576, 2011.
34. Kostiuk MA, Keller BO, Berthiaume LG. Palmitoylation of ketogenic enzyme HMGCS2 enhances its interaction with PPAR and transcription at the Hmgcs2 PPRE. FASEB J 24: 1914-1924, 2010.
35. Kotronen A, Yki-Järvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 28: 27-38, 2008.
36. Later CZ, Yeh MM, Van Rooyen DM, Brooling J, Ghatora K, Farrell GC. Peroxisome proliferator-activated receptor-, Wy14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with nonalcoholic steatohepatitis. J Gastroenterol Hepatol 27: 341-350, 2012.
37. Lebovics E, Rubin J. Non-alcoholic fatty liver disease (NAFLD): why you should care, when you should worry, what you should do. Diabetes Metab Res Rev 27: 419-424, 2011.
38. Lee AH, Scapa EF, Cohen DE, Glimcher LH. Regulation of hepatic lipogenesis by the transcription factor XBP1. Science 320: 1492-1496, 2008.
39. Lee GY, Kim NH, Zhao ZS, Cha BS, Kim YS. Peroxisomal-proliferatoractivated receptor activates transcription of the rat hepatic malonyl-CoA decarboxylase gene: a key regulation of malonyl-CoA level. Biochem J 378: 983-990, 2004.
40. Lee MS, Kim D, Jo K, Hwang JK. Nordihydroguaiaretic acid protects against high-fat diet-induced fatty liver by activating AMP-activated protein kinase in obese mice. Biochem Biophys Res Commun 401: 92-97, 2010.
41. Lelliott CJ, Medina-Gomez G, Petrovic N, Kis A, Feldman HM, Bjursell M, Parker N, Curtis K, Campbell M, Hu P, Zhang D, Litwin SE, Zaha VG, Fountain KT, Boudina S, Jimenez-Linan M, Blount M, Lopez M, Meirhaeghe A, Bohlooly YM, Storlien L, Strömstedt M, Snaith M, Oresic M, Abel ED, Cannon B, Vidal-Puig A. Ablation of PGC-1 results in defective mitochondrial activity, thermogenesis, hepatic function, and cardiac performance. PLoS Biol 4: e369, 2006.
42. Leone TC, Lehman JJ, Finck BN, Schaeffer PJ, Wende AR, Boudina S, Courtois M, Wozniak DF, Sambandam N, Bernal-Mizrachi C, Chen Z, Holloszy JO, Medeiros DM, Schmidt RE, Saffitz JE, Abel ED, Semenkovich CF, Kelly DP. PGC-1 deficiency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis. PLoS Biol 3: e101, 2005.
43. Leone TC, Weinheimer CJ, Kelley DP. A critical role for the peroxisome proliferator-activated receptor (PPAR) in the cellular fasting response: The PPAR-null mouse as a model of fatty acid oxidation disorders. Proc Natl Acad Sci USA 96: 7473-7478, 1999.
44. Li Y, Xu S, Mihaylova MM, Zheng B, Hou X, Jiang B, Park O, Luo Z, Lefai E, Shyy JY, Gao B, Wierzbicki M, Verbeuren TJ, Shaw RJ, Cohen RA, Zang M. AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulinresistant mice. Cell Metab 13: 376-388, 2011.
45. Lin J, Handschin C, Spiegelman BM. Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab 1: 361-370, 2011.
46. Ma L, Robinson LN, Towle HC. ChREBP·Mlx is the principal mediator of glucose-induced gene expression in the liver. J Biol Chem 281: 28721-28730, 2006.
47. Mannaerts GP, Debeer LJ, Thomas J, De Schepper PJ. Mitochondrial and peroxisomal fatty acid oxidation in liver homogenates and isolated hepatocytes from control and clofibrate-treated rats. J Biol Chem 254: 4585-4595, 1979.
48. Matsusue K, Haluzik M, Lambert G, Yim SH, Gavrilova O, Ward JM, Brewer B Jr, Reitman M, Gozalez FJ. Liver-specific disruption of PPAR in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. J Clin Invest 111: 737-747, 2003.
49. McGarry J, Brown N. The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis. J Biochem 244: 1-14, 1997.
50. Mencin AA, Lavine JE. Nonalcoholic fatty liver disease in children. Curr Opin Clin Nutr Metab Care 14: 151-157, 2011.
51. Moon YA, Liang G, Xie X, Frank-Kamenetsky M, Fitzgerald K, Koteliansky V, Brown MS, Goldstein JL, Horton JD. The Scap/SREBP pathway is essential for developing diabetic fatty liver and carbohydrateinduced hypertriglyceridemia in animals. Cell Metab 15: 240-246, 2012.
52. Moore JB. Non-alcoholic fatty liver disease: the hepatic consequences of obesity and the metabolic syndrome. Proc Nutr Soc 69: 211-220, 2010.
53. Oosterveer MH, Grefhorst A, van Dijk TH, Havinga R, Staels B, Kuipers F, Groen AK. Fenofibrate simultaneously induces hepatic fatty acid oxidation, synthesis, and elongation in mice. J Biol Chem 284: 34036-34044, 2009.
54. Oyadomari S, Harding HP, Zhang Y, Oyadomari M, Ron D. Dephosphorylation of translation initiation factor 2 enhances glucose tolerance and attenuates hepatosteatosis in mice. Cell Metab 7: 520-532, 2008.
55. Pellemounter MA, Cullen MJ, Baker MB, Hecht R, Winters D, Boone T, Collins F. Effect of obese gene product on body weight regulation in ob/ob mice. Science 269: 540-543, 1995.
56. Postic C, Dentin R, Denechaud PD. ChREBP, a transcriptional regulator of glucose and lipid metabolism. Annu Rev Nutr 27: 179-192, 2007.
57. Postic C, Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest 118: 829-838, 2008.
58. Pyper SR, Viswakarma N, Yu S, Reddy JK. PPAR: energy combustion, hypolipidemia, inflammation and cancer. Nucl Recept Signal 8: e002, 2010.
59. Rakhshandehroo M, Knoch B, Müller M, Kersten S. Peroxisome proliferator-activated receptor target genes. PPAR Res 2010: 612089, 2010. Epub 2010 Sep 26.
60. Reed MJ, Meszaros K, Entes LJ, Claypool MD, Pinkett JG, Brignetti D, Luo J, Khandwala A, Reaven GM. Effect of masoprocol on carbohydrate and lipid metabolism in a rat model of type II diabetes. Diabetologia 42: 102-106, 1999.
61. Ren LP, Chan SMH, Zeng XY, Laybutt DR, Iseli TJ, Sun RQ, Kraegen EW. Differing endoplasmic reticulum stress response to excess lipogenesis versus lipid oversupply in relation to hepatic steatosis and insulin resistance. PLoS ONE 7: e30816, 2012.
62. Repa JJ, Liang G, Bashmakov Y, Lobaccaro JMA, Shimomura I, Shan B, Brown MS, Goldstein JL, Mangelsdorf DJ. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXR and LXR. Genes Dev 14: 2819-2830, 2000.
63. Rutkowski DT, Wu J, Back SH, Callaghan MU, Ferris SP, Iqbal J, Clark R, Miao H, Hassler JR, Fornek J, Katze MG, Hussain MM, Song B, Swathirajan J, Wang J, Yau GD, Kaufman RJ. UPR pathways combine to prevent hepatic steatosis caused by ER stress-mediated suppression of transcriptional master regulators. Dev Cell 15: 829-840, 2008.
64. Savage DB, Semple RK. Recent insight into fatty liver, metabolic dyslipidemia and their links to insulin resistance. Curr Opin Lipidol 21: 329-336, 2010.
65. Schultz JR, Tu H, Luk A, Repa JJ, Medina JC, Li L, Schwender S, Wang S, Thoolen M, Mangelsdorf DJ, Lustig KD, Shan B. Role of LXRs in control of lipogenesis. Genes Dev 14: 2831-2838, 2000.
66. Shimomura I, Bashmakov Y, Horton JD. Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus. J Biol Chem 274: 30028-30032, 1999.
67. Smith BW, Adams LA. Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment. Nat Rev Endocrinol 7: 456-465, 2011.
68. Smith BW, Adams LA. Nonlcoholic fatty liver disease. Crit Rev Clin Lab Sci 48: 97-113, 2011.
69. Stefan N, Kantartizis K, Häring HU. Causes and metabolic consequences of fatty liver. Endocr Rev 29: 939-960, 2008.
70. Strable MS, Ntambi JM. Genetic control of de novo lipogenesis: role in diet-induced obesity. Crit Rev Biochem Mol Biol 45: 199-214, 2010.
71. Sudgen MC, Bulmer K, Gibbons GF, Knight BL, Holness MJ. Peroxisome-proliferator-activated receptor-(PPAR) deficiency leads to dysregulation of hepatic lipid and carbohydrate metabolism by fatty acids. Biochem J 364: 361-368, 2002.
72. Takaishi K, Duplomb L, Wang MY, Li J, Unger RH. Hepatic Insig-1 or Insig-2 overexpression reduces lipogenesis in obese Zucker diabetic fatty rats and in fasted/refed normal rats. Proc Natl Acad Sci USA 101: 7106-7111, 2004.
73. Thoma C, Day CP, Trenell MI. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. J Hepatol 56: 255-266, 2012.
74. Tiniakos DG, Vos MB, Brunt EM. Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu Rev Pathol 5: 145-171, 2010.
75. Uyeda K, Repa JJ. Carbohydrate response element binding protein, ChREBP, a transcription factor coupling hepatic glucose utilization and lipid synthesis. Cell Metab 4: 107-110, 2006.
76. van Wagner LB, Rinella ME. The role of insulin sensitizing agents in the treatment of nonalcoholic steatohepatitis. Therap Adv Gastroenterol 4: 249-263, 2011.
77. Viollet B, Guigas B, Leclerc J, Hébrad S, Lantier L, Mounier R, Andreelli F, Foretz M. AMP-activated protein kinase in the regulation of hepatic energy metabolism: from physiology to therapeutic perspectives. Acta Physiol (Oxf) 196: 81-98, 2009.
78. Yahagi N, Shimano H, Hasty AH, Matsuzaka T, Ide T, Yoshikawa Y, Amemiya-Kudo M, Tomita S, Okazaki H, Tamura Y, Iizuka Y, Ohashi K, Osuga J, Hareda K, Gotoda T, Nagai R, Ishibashi S. Absence of sterol regulatory element-binding protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in Lepob/Lepob mice. J Biol Chem 277: 19353-19357, 2002.
79. Zhang BB, Zhou G, Li C. AMPK: an emerging drug target for diabetes and metabolic syndrome. Cell Metab 9: 407-416, 2009.
80. Zhang K, Wang S, Malhotra J, Hassler JR, Back SH, Wang G, Chang L, Xu W, Miao H, Leonardi R, Chen YE, Jackowski S, Kaufman RJ. The unfolded protein response transducer IRE1a prevents ER stressinduced hepatic steatosis. EMBO J 30: 1357-1375, 2011.